Koyfin Home > Directory > Health Care > Rigel Pharmaceuticals > Net Debt / EBITDA

Rigel Pharmaceuticals Net Debt / EBITDA Chart (RIGL)

Rigel Pharmaceuticals annual/quarterly Net Debt / EBITDA from 2010 to 2020. Net Debt / EBITDA is a measure of leverage for a company by dividing the Debt less Cash on hand vs. EBITDA.
  • Rigel Pharmaceuticals Net Debt / EBITDA for the quarter ending June 06, 2020 was $1m a -106.14% decrease of -1m year over year
  • Rigel Pharmaceuticals Net Debt / EBITDA for the last 12 months ending June 06, 2020 was $2m a 36.10% increase of 1m year over year
  • Rigel Pharmaceuticals Annual Net Debt / EBITDA for 2019 was $1m a -80.16% decrease of -1m from 2018
  • Rigel Pharmaceuticals Annual Net Debt / EBITDA for 2018 was $2m a 17.98% increase of 0m from 2017
  • Rigel Pharmaceuticals Annual Net Debt / EBITDA for 2017 was $1m a 18.89% increase of 0m from 2016
Other Ratios Metrics:
  • Rigel Pharmaceuticals Total Debt / Capital for the quarter ending September 09, 2011 was $0m a -823.31% decrease of 0m year over year
  • Rigel Pharmaceuticals Other Liabilities for the quarter ending December 12, 2018 was $1m a 91.46% increase of 1m year over year
  • Rigel Pharmaceuticals Total Debt / Equity for the quarter ending September 09, 2011 was $0m a -827.75% decrease of 0m year over year
View Chart On Koyfin

Quarterly RIGL Net Debt / EBITDA Data

06/2020$1m
03/2020$-1m
12/2019$1m
09/2019$1m
06/2019$1m
03/2019$1m
12/2018$-12m
09/2018$1m
06/2018$1m
03/2018$1m

Annual RIGL Net Debt / EBITDA Data

2019$1m
2018$2m
2017$1m
2016$1m
2015$3m
2014$2m
2013$2m
2012$3m
2011$3m
2010$-5m